# A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Source: https://onco.cc/trials/nct05643742/  
OnCo record `nct05643742` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CTX112 in hodgkin lymphoma and non-hodgkin lymphoma, run by CRISPR Therapeutics AG, now recruiting.

## Summary

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies is a phase 1/2 interventional study registered as NCT05643742 by CRISPR Therapeutics AG, with 120 participants planned, started 2023-03-10 and due to reach its primary completion in 2030-01. Interventions recorded: CTX112. Conditions listed: B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05643742
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies
- Sponsor: CRISPR Therapeutics AG
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT05643742: https://clinicaltrials.gov/study/NCT05643742

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [CTX112](https://onco.cc/drugs/ctx112/)

---
JSON: https://onco.cc/api/v1/entities/nct05643742.json